Authors: | Bonifant, C. L.; Jackson, H. J.; Brentjens, R. J.; Curran, K. J. |
Article Title: | Toxicity and management in CAR T-cell therapy |
Abstract: | T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, "on target/off tumor" recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management. |
Keywords: | review; neurotoxicity; t lymphocyte; dexamethasone; carcinogenesis; hematologic malignancy; cardiotoxicity; antigen recognition; graft versus host reaction; chimeric antigen receptor; cell therapy; immunosuppressive treatment; anaphylaxis; ganciclovir; t lymphocyte activation; intracellular signaling; suicide gene; cytokine release syndrome; fk 506 binding protein; tocilizumab; human; priority journal |
Journal Title: | Molecular Therapy - Oncolytics |
Volume: | 3 |
ISSN: | 2372-7705 |
Publisher: | Cell Press |
Date Published: | 2016-04-20 |
Start Page: | 16011 |
Language: | English |
DOI: | 10.1038/mto.2016.11 |
PROVIDER: | scopus |
PMCID: | PMC5008265 |
PUBMED: | 27626062 |
DOI/URL: | |
Notes: | Review -- Export Date: 2 June 2016 -- Source: Scopus |